지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이 논문의 연구 히스토리 (2)
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Vascular endothelial growth factor (VEGF-A) is a major regulator of angiogenesis and vascular permeability. VEGF-A plays an important role in a wide variety of retinal diseases. Therefore, intravitreal injection of anti-VEGF agents is increasingly used for the treatment of various vasoproliferative or exudative retinal diseases. There are several anti- VEGF drugs available that are currently used, but three are most commonly used in practice. They are ranibizumab, bevacizumab, and aflibercept. Ranibizumab is a humanized monoclonal antibody fragment targeting VEGF-A, but bevacizumab, commonly used off-label, is a humanized full-length anti-VEGF antibody. Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1. These anti-VEGF therapies have resulted in unprecedented visual and anatomic outcomes, especially in patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Visual stabilization or clinically significant visual improvement can be expected if intravitreal injections of anti-VEGF agents are properly provided for patients with neovascular AMD or DME in the course of the disease. Treating retinal diseases with intravitreal injection of anti-VEGF agents may have potential side effects. Systemic adverse effects attributable to VEGF inhibition may cause thromboembolic events. Acute endophthalmitis is the most feared injection-related ocular side effect. The development of anti-VEGF agents for various retinal diseases provides a safe and effective treatment. There is no doubt that further advances in anti-VEGF therapy can be expected soon.
목차
등록된 정보가 없습니다.
참고문헌 (6)
참고문헌 신청
Rosenfeld PJ / 2006 / Ranibizumab for neovascular age-related macular degeneration / N Engl J Med 355:1419~1431
CATT Research Group / 2011 / Ranibizumab and bevacizumab for neovascular age-related macular degeneration / N Engl J Med 364:1897~1908
Heier JS / 2012 / VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration / Oph-thalmology 119:2537~2548
Diabetic Retinopathy Clinical Research Network / 2010 / Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema / Ophthalmology 117:1064~1077
Diabetic Retinopathy Clinical Research Network / 2015 / Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema / N Engl J Med 372:1193~1203
CATT Research Group / 2011 / Ranibizumab and bevacizumab for neovascular age-related macular degeneration / N Engl J Med 364:1897~1908
Heier JS / 2012 / VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration / Oph-thalmology 119:2537~2548
Diabetic Retinopathy Clinical Research Network / 2010 / Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema / Ophthalmology 117:1064~1077
Diabetic Retinopathy Clinical Research Network / 2015 / Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema / N Engl J Med 372:1193~1203
이 논문의 저자 정보
최근 본 자료
댓글(0)
0